A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead resubmits application to FDA for approval of long-acting injectable HIV drug lenacapavir after FDA refused authorization in February due to drug’s compatibility with borosilicate glass vial; Gilead now using aluminosilicate glass vial for drug
Published: June 29, 2022 by SeeNews Pharmaceuticals
Gilead signs WHO’s Kigali Declaration to prevent, control, eliminate neglected tropical diseases; Gilead to continue to donate drugs to treat, eliminate parasitic disease visceral leishmaniasis in tropical, subtropical regions
Published: June 29, 2022 by SeeNews Pharmaceuticals
Gilead names Stacey Ma Executive VP for pharmaceutical development, manufacturing, replacing Taiyin Yang who is retiring; Gilead to focus manufacturing on West Coast of US, with plans to expand manufacturing near current Oceanside, California, facility
Published: June 03, 2022 by FiercePharma
FDA lifts clinical hold on Gilead’s injectable lenacapavir HIV treatment, pre-exposure prophylaxis as Gilead changes borosilicate glass vials to aluminosilicate glass vials; hold was from concerns about drug’s compatibility with borosilicate vials
Published: May 18, 2022 by Zack's Commentary
Gilead and Dragonfly Therapeutics announce strategic research collaboration to develop natural killer cell engagers for oncology, inflammation; Gilead makes US$300.0M payment to Dragonfly for rights to investigational immunotherapy program DF7001
Published: May 04, 2022 by Business Wire

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count